Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SYK vs PHG: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SYK Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

SYK Overall Winner 6-Pillar Tally: SYK 5 – 1 PHG Matrix Metrics: SYK 7 – 3 PHG

As of Nov 16, 2026, Stryker Corporation (SYK) is the stronger overall head-to-head candidate over Koninklijke Philips N.V. (PHG) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SYK carries a Unified Composite Score of 46.5/100 (HOLD) at $310.79 (19.0x Forward P/E, 24.0% operating margin), whereas PHG carries 28.4/100 (SELL) at $30.21 (14.9x Forward P/E, 8.8% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SYK vs PHG
SYK NYSE Head-to-Head Winner
Stryker Corporation
Surgical & Medical Instruments & Apparatus
$310.79
+0.37% 1D
Market Cap $118.9B
TTM Revenue $26.3B
Forward P/E 19.0x
Beta / 30D Vol 0.22β · 50% Vol
Unified Composite Score
46.5 / 100 HOLD
Tech 37.0 Fund 49.0 Flow 58.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.5 · SMA20: $312.55 · SMA50: $292.40
PHG NYSE
Koninklijke Philips N.V.
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
$30.21
-0.43% 1D
Market Cap $29.6B
TTM Revenue $8.71B
Forward P/E 14.9x
Beta / 30D Vol 0.73β · 38% Vol
Unified Composite Score
28.4 / 100 SELL
Tech 50.0 Fund 23.0 Flow 54.0 Mom 11.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.4% over 20 days), RSI 71
RSI-14: 71.0 · SMA20: $28.51 · SMA50: $26.23

6-Pillar Scorecard Institutional Category Breakdown (SYK 5 – 1 PHG)

Columns: Metric · SYK · PHG
1. Valuation Multiples PHG
Forward P/E 19.0x 14.9x
Trailing P/E 33.3x 63.2x
PEG Ratio 1.54x 0.90x
EV / Revenue 5.0x 3.7x
2. Growth & Scale SYK
Revenue Growth (YoY) +7.6% +2.1%
Earnings Growth (YoY) -11.7% -85.4%
TTM Revenue (USD) $26.3B $8.71B
Market Cap $118.9B $29.6B
3. Profitability & Quality SYK
Gross Margin 65.7% 46.4%
Operating Margin 24.0% 8.8%
Net Profit Margin 13.8% 5.4%
Return on Equity (ROE) 16.0% 8.6%
4. Balance Sheet & Cash Flow SYK
Cash Generation (TTM) $4.57B $895M
Cash Flow Margin 17.4% 10.3%
Net Cash / Leverage $11.7B Net Debt (0.64x D/E) $2.64B Net Debt (0.70x D/E)
Dividend Yield 1.10% None (0.00%)
5. Options & Positioning SYK
Options Structure Phase SURGE SURGE
Current IV / %ile 28.1% (5th %ile) 25.8% (2nd %ile)
Put/Call OI Skew 0.30x (Call-Skewed) 0.30x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat SYK
OpEx & R&D Intensity 41.7% of Rev ($11.0B) 37.6% of Rev ($3.27B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Concentrated Oligopoly Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SYK (7) vs PHG (3)
Institutional Metric SYK PHG Criterion Row Edge
Market Capitalization
Scale
$118.9B $29.6B Larger Scale SYK
Trailing P/E Ratio
Valuation
33.3x 63.2x Lower Multiple SYK
Forward P/E Ratio
Valuation
19.0x 14.9x Lower Multiple PHG
Revenue Growth (YoY)
Growth
+7.6% +2.1% Higher Growth SYK
Operating Margin (TTM)
Profitability
24.0% 8.8% Higher Margin SYK
Net Profit Margin
Profitability
13.8% 5.4% Higher Margin SYK
Return on Equity (ROE)
Capital Efficiency
16.0% 8.6% Higher ROE SYK
52-Week Range Position
Momentum
36% ($267–$389) 67% ($24–$33) Stronger Trend PHG
Beta / 30D Volatility
Risk Regime
0.22β · 50% Vol 0.73β · 38% Vol Lower Realized Risk PHG
Unified Institutional Score
Composite Signal
46.5 / 100 (HOLD) 28.4 / 100 (SELL) Higher Composite SYK
Trailing 12M Revenue (USD)
Operating Scale
$26.3B $8.71B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
65.7% 46.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.54x PEG · 5.0x EV/Rev 0.90x PEG · 3.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$4.57B ($11.7B Net Debt (0.64x D/E)) $895M ($2.64B Net Debt (0.70x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PHG +11.9 pp
SYK: +5.47% · PHG: +17.37%
3M Horizon PHG +17.69 pp
SYK: -6.21% · PHG: +11.48%
6M Horizon PHG +16.75 pp
SYK: -0.78% · PHG: +15.97%
1Y Horizon PHG +21.23 pp
SYK: -16.77% · PHG: +4.46%

Financial Trajectory Annualized Quarterly Run-Rate Revenue & Operating Margin Trajectory (USD-Normalized)

Split-Invariant USD Revenue & Operating Margin (%)
Period SYK Revenue PHG Revenue SYK Op. Margin PHG Op. Margin Margin Leader
Q3 '25 $24.2B $8.44B 19.9% 7.7% SYK
Q4 '25 $28.7B $10.0B 25.3% 11.1% SYK
Q1 '26 $24.1B $7.66B 15.5% 6.2% SYK
Q2 '26 $26.4B $8.55B 25.2% 14.0% SYK
Q3 '26 $26.1B $8.62B 20.4% 3.8% SYK

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SYK SURGE
8d in phase · OBV DISTRIBUTION
Current IV 28.1%
IV Percentile 5th %ile
Put/Call OI Skew 0.30x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact SYK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PHG SURGE
8d in phase · OBV DISTRIBUTION
Current IV 25.8%
IV Percentile 2nd %ile
Put/Call OI Skew 0.30x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact PHG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SYK Moat Profile Concentrated Oligopoly Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $118.9B market capitalization and 24.0% operating margin.
OpEx & R&D Reinvestment 41.7% of Rev ($11.0B)
90D Engineering Disclosures 0 Published · Surgical Robotics
PHG Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $29.6B market capitalization and 8.8% operating margin.
OpEx & R&D Reinvestment 37.6% of Rev ($3.27B)
90D Engineering Disclosures 0 Published

Investor FAQ SYK vs PHG Key Questions & Quantitative Answers

As of Nov 16, 2026, Stryker Corporation (SYK) is the stronger overall head-to-head candidate over Koninklijke Philips N.V. (PHG) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SYK carries a Unified Composite Score of 46.5/100 (HOLD) at $310.79 (19.0x Forward P/E, 24.0% operating margin), whereas PHG carries 28.4/100 (SELL) at $30.21 (14.9x Forward P/E, 8.8% operating margin). Technically, SYK sits in a Neutral phase (RSI 51.5, SURGE options structure) and PHG sits in a Markup phase (RSI 71.0, SURGE options structure).

SYK leads the Growth & Scale pillar: SYK posts +7.6% YoY revenue growth and -11.7% YoY earnings growth on $26.3B TTM revenue (65.7% gross margin, 24.0% operating margin), compared with PHG at +2.1% YoY revenue growth and -85.4% YoY earnings growth on $8.71B TTM revenue (46.4% gross margin, 8.8% operating margin). Across the 5-period historical trajectory (Q3 '25 to Q3 '26), SYK cumulative revenue shifted +7.6% while PHG shifted +2.1%. In operating R&D and SG&A reinvestment, SYK deploys 41.7% of Rev ($11.0B) (0 90-day corporate R&D disclosures) versus 37.6% of Rev ($3.27B) (0 disclosures) for PHG.

PHG screens cheaper on headline valuation multiples. SYK trades at 19.0x Forward P/E, 33.3x Trailing P/E, 1.54x PEG, and 5.0x EV/Revenue (17.4% FCF margin), whereas PHG trades at 14.9x Forward P/E, 63.2x Trailing P/E, 0.90x PEG, and 3.7x EV/Revenue (10.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYK (16.0% ROE) versus PHG (8.6% ROE) capital efficiency.

In options market volatility and institutional positioning, SYK carries 28.1% implied volatility (5th %ile, Compressed (<25th %ile)), a 0.30x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.22β · 50% Vol realized risk). By comparison, PHG carries 25.8% implied volatility (2nd %ile, Compressed (<25th %ile)), a 0.30x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.73β · 38% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.